Aqua Bio Technology Asa · OSL:ABTEC
Aqua Bio Technology Asa — Q4 2015 Earnings Presentation
11 slides from Aqua Bio Technology Asa's earnings presentation, Feb 10, 2016
Slide 1: Fourth Quarter and Full Year 2015 Results Presentation
Fourth Quarter and Full Year 2015 Results Presentation 10 February 2016 1
Slide 2: 2015 Highlights
2015 Highlights • Best year in Company history – All time high revenues – 55 percent EBITDA margin • Further improved cash position – NOK 42 million cash reserve • The Board of Directors contemplates dividend payment for 2015 – NOK 1.50 per share – Expected to be formally proposed to AGM upon audite
Slide 3: Income Statement
Income Statement NOK million Q4 2015 Q342014 FY 2015 FY 2014 Income 10.3 5.8 38.9 22.5 Operating costs -4.0 -3.9 -17.7 -16.6 EBITDA 6.3 1.9 21.2 5,8 EBIT 5.4 0.3 15.4 -0.5 EBT 4.7 1.5 15.0 0.9 Net result 4.7 1.5 15.0 0.9 EBITDA margin 61.2% 32.8% 54.5% 25.8%
Slide 4: Income and results development
Income and results development NOK mill. 12 7 70,0 % 10 6 60,0 % 5 50,0 % 8 4 40,0 % 6 3 30,0 % 4 2 20,0 % 2 1 10,0 % 0 0 0,0 % Q3 14 Q4 14 Q1 15 Q2 15 Q3 15 Q4 15 Q3 14 Q4 14 Q1 15 Q2 15 Q3 15 Q4 15 Other income Sales EBITDA (NOK mill) EBITDA margin (%) Sales EBITDA 4
Slide 5: Cash position further strengthened
Cash position further strengthened NOK mill 45 40 • NOK 42.0 million cash and cash 35 equivalents as of 31 December 2015 30 • ABT first dividend payment in Q2 2015 (NOK 6.4 million) 25 20 Q1 14 Q2 14 Q3 14 Q4 14 Q1 15 Q2 15 Q3 15 Q4 15 5
Slide 6: Balance Sheet
Balance Sheet NOK million 31 Dec 2015 30 Sep 2015 31 Dec 2014 Fixed assets 8.6 9.7 12.4 Current assets 75.0 68.7 63.4 - of which is cash 42.0 35.2 29.2 Total equity 74.2 69.5 66.3 Long term debt 5.0 5.3 5.6 Short term debt 4.3 3.5 3.9 Total balance 83.6 78.4 75.8 Equity ratio 88.8% 88.7% 87.5%
Slide 7: Cash flow
Cash flow NOK million (full year) 2015 2014 Cash at beginning of period 29.2 27.0 From operations 21.9 7.5 From investments -2.0 -2.2 From financing -6.4 -3.8 Currency effects -0.7 0.8 Cash at end of period 42.0 29.2 Cash change in period 13.5 1.4 • ABT paid its shareholders a total of NOK 6.4 milli
Slide 8: Expanding the business case
Expanding the business case • ABT holds two main strategic advantages – Experience in commercialization of new bio technology – Financial flexibility • Strategy: Expanding the technology platform through in-licensing – Biotech developers often lack commercial experience – Securing ABT’s long term va
Slide 9: Outlook
Outlook • Continued strong revenue stream – Contracted revenue through exclusivity and royalty payments continue until 2017 – Commercial success of exclusivity partners represent upside potential • Expanded business model offers additional potential – Evaluation of in-licensing candidates continues
Slide 10: 1st Quarter 2016 Results May 2016
1st Quarter 2016 Results 11 May 2016
Slide 11: Investor contact
Investor contact Arvid Lindberg, CEO +47 9824 5410 arvid@aquabiotech.no www.aquabiotechnology.com